Published on 17 Feb 2025
• The President of India Smt. Droupadi Murmu launched India’s first home-grown anti Cancer CAR-T cell therapy, NexCAR19.
• The NexCAR19 is a type of CAR-T cell therapy designed to target cancer cells that carry the CD19 protein, a protein that acts like a flag on cancer cells.
• It was developed by a collaboration involving ImmunoACT, an incubated company at the IIT Bombay, Prof. Rahul Purwar and his team from the Department of Biosciences and Bioengineering at IIT Bombay and Tata Memorial Centre.
• NexCAR19 is approved for the treatment of B-cell lymphomas and B-Acute Lymphoblastic Leukaemia (B-ALL) in patients who have not responded to standard treatments like chemotherapy.
CAR-T cell therapy is a form of immunotherapy that involves taking a patient’s T cells (a type of immune cell), modifying them in a lab to target and destroy cancer cells, and then reintroducing them into the patient’s body
NexCAR19
Biotechnology
CAR-T cell therapy
immunotherapy
Cancer